Successful treatment of refractory metastatic histiocytic sarcoma with alemtuzumab

Cancer

Volumn 118, Issue 15, 2012, Pages 3719-3724

  Shukla, Neerav ^a   Kobos, Rachel ^a   Renaud, Thomas ^a   Teruya Feldstein, Julie ^a   Price, Anita ^a   McAllister Lucas, Linda ^b   Steinherz, Peter ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

alemtuzumab; antibody; histiocytic sarcoma; metastatic; refractory

Indexed keywords

ALEMTUZUMAB; ASPARAGINASE MACROGOL; CD31 ANTIGEN; CD4 ANTIGEN; CD45 ANTIGEN; CD45RO ANTIGEN; CD52 ANTIGEN; CD68 ANTIGEN; CLADRIBINE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; HEMOGLOBIN; IFOSFAMIDE; IMMUNOGLOBULIN; KI 67 ANTIGEN; LACTATE DEHYDROGENASE; LEUKOSIALIN; LYSOZYME; METHOTREXATE; PREDNISONE; PROTEIN S 100; THALIDOMIDE; TIOGUANINE; UNINDEXED DRUG; VIMENTIN; VINCRISTINE;

ADOLESCENT; ADVANCED CANCER; AGITATION; ARTICLE; ARTIFICIAL VENTILATION; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CASE REPORT; CHILD; COMPUTER ASSISTED TOMOGRAPHY; CONSOLIDATION CHEMOTHERAPY; DETERIORATION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXTUBATION; FEMALE; FEVER; FOLLOW UP; HEPATOSPLENOMEGALY; HISTIOCYTIC SARCOMA; HUMAN; HUMAN TISSUE; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOHISTOCHEMISTRY; INDUCTION CHEMOTHERAPY; INFECTION; INTENSIVE CARE; KIDNEY METASTASIS; LAPAROTOMY; LEG PAIN; LEUKOCYTE COUNT; LIVER BIOPSY; LIVER FIBROSIS; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE BIOPSY; LYMPHADENOPATHY; LYMPHOCYTOPENIA; MEDIASTINUM; METABOLIC ACIDOSIS; METASTATIC HISTIOCYTIC SARCOMA; NERVE SHEATH TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; PALLOR; PANCREAS; PERITONEAL BIOPSY; PETECHIA; PLEURA; POSITRON EMISSION TOMOGRAPHY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; RASH; RETROPERITONEAL TUMOR; SPLEEN METASTASIS; TACHYCARDIA; TACHYPNEA; THROMBOCYTE COUNT; TUMOR REGRESSION;

ADOLESCENT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; FEMALE; HISTIOCYTIC SARCOMA; HUMANS; INFANT; NEOPLASM METASTASIS; RETREATMENT; THALIDOMIDE;

EID: 84864117862     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26712     Document Type: Article

References (33)

1. Weiss LM, Crogan EM, Muller-Hermelink HK, et al. Histiocytic sarcoma. In:, Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001.
2. Vos JA, Abbondanzo SL, Barekman CL, Andriko JW, Miettinen M, Aguilera NS,. Histiocytic sarcoma: a study of 5 cases including the histiocyte marker CD163. Mod Pathol. 2005; 18: 693-704.
3. Hanson CA, Jaszcz W, Kersey JH, et al. True histiocytic lymphoma: histopathologic, immunophenotypic and genotypic analysis. Br J Haematol. 1989; 73: 187-198.
4. Lauritzen AF, Delsol G, Hansen NE, et al. Histiocytic sarcomas and monoblastic leukemias. A clinical, histologic, and immunophenotypical study. Am J Clin Pathol. 1994; 102: 45-54.
5. Pileri SA, Grogan TM, Harris NL, et al. Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases. Histopathology. 2002; 41: 1-29.
6. Bouabdallah R, Abena P, Chetaille B, et al. True histiocytic lymphoma following B-acute lymphoblastic leukaemia: case report with evidence for a common clonal origin in both neoplasms. Br J Haematol. 2001; 113: 1047-1050.
7. Buonocore S, Valente AL, Nightingale D, Bogart J, Souid AK,. Histiocytic sarcoma in a 3-year-old male: a case report. Pediatrics. 2005; 116: e322-e325.
8. Copie-Bergman C, Wotherspoon AC, Norton AJ, Diss TC, Isaacson PG,. True histiocytic lymphoma: a morphologic, immunohistochemical, and molecular genetic study of 13 cases. Am J Surg Pathol. 1998; 22: 1386-1392.
9. Hornick JL, Jaffe ES, Fletcher CD,. Extranodal histiocytic sarcoma: clinicopathologic analysis of 14 cases of a rare epithelioid malignancy. Am J Surg Pathol. 2004; 28: 1133-1144.
10. Kamel OW, Gocke CD, Kell DL, Cleary ML, Warnke RA,. True histiocytic lymphoma: a study of 12 cases based on current definition. Leuk Lymphoma. 1995; 18: 81-86.
11. Murarescu ED, Lighezan R, Negru D, Chiselita IR, Plamadeala P, Mihailovici MS,. Histiocytic sarcoma associated with Hodgkin's disease. Rom J Morphol Embryol. 2005; 46: 183-187.
12. Hale G, Swirsky DM, Hayhoe FG, Waldmann H,. Effects of monoclonal anti-lymphocyte antibodies in vivo in monkeys and humans. Mol Biol Med. 1983; 1: 321-334.
13. Hale G, Dyer MJ, Clark MR, et al. Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet. 1988; 2: 1394-1399.
14. Calne R, Friend P, Moffatt S, et al. Prope tolerance, perioperative Campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet. 1998; 351: 1701-1702.
15. Gruessner RW, Kandaswamy R, Humar A, Gruessner AC, Sutherland DE,. Calcineurin inhibitor- and steroid-free immunosuppression in pancreas-kidney and solitary pancreas transplantation. Transplantation. 2005; 79: 1184-1189.
16. Tryphonopoulos P, Madariaga JR, Kato T, et al. The impact of Campath 1H induction in adult liver allotransplantation. Transplant Proc. 2005; 37: 1203-1204.
17. Tzakis AG, Tryphonopoulos P, Kato T, et al. Intestinal transplantation: advances in immunosuppression and surgical techniques. Transplant Proc. 2003; 35: 1925-1926.
18. Ona ET, Danguilan RA, Africa J, et al. Use of alemtuzumab (Campath-1H) as induction therapy in pediatric kidney transplantation. Transplant Proc. 2008; 40: 2226-2229.
19. Bertz H, Spyridonidis A, Wasch R, Grullich C, Egger M, Finke J,. A novel GVHD-prophylaxis with low-dose alemtuzumab in allogeneic sibling or unrelated donor hematopoietic cell transplantation: the feasibility of de-escalation. Biol Blood Marrow Transplant. 2009; 15: 1563-1570.
20. Gupta V, Ball SE, Sage D, et al. Marrow transplants from matched unrelated donors for aplastic anaemia using alemtuzumab, fludarabine and cyclophosphamide based conditioning. Bone Marrow Transplant. 2005; 35: 467-471.
21. Morris E, Thomson K, Craddock C, et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood. 2004; 104: 3865-3871.
22. Ahmed N, Leung KS, Rosenblatt H, et al. Successful treatment of stem cell graft failure in pediatric patients using a submyeloablative regimen of campath-1H and fludarabine. Biol Blood Marrow Transplant. 2008; 14: 1298-1304.
23. Gribben JG, Hallek M,. Rediscovering alemtuzumab: current and emerging therapeutic roles. Br J Haematol. 2009; 144: 818-831.
24. Khorana A, Bunn P, McLaughlin P, Vose J, Stewart C, Czuczman MS,. A phase II multicenter study of CAMPATH-1H antibody in previously treated patients with nonbulky non-Hodgkin's lymphoma. Leuk Lymphoma. 2001; 41: 77-87.
25. Ravandi F, Aribi A, O'Brien S, et al. Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms. J Clin Oncol. 2009; 27: 5425-5430.
26. Williams KM, Higman MA, Chen AR, et al. Successful treatment of a child with late-onset T-cell post-transplant lymphoproliferative disorder/lymphoma. Pediatr Blood Cancer. 2008; 50: 667-670.
27. Angiolillo AL, Yu AL, Reaman G, Ingle AM, Secola R, Adamson PC,. A phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: a Children's Oncology Group report. Pediatr Blood Cancer. 2009; 53: 978-983.
28. Ambrose LR, Morel AS, Warrens AN,. Neutrophils express CD52 and exhibit complement-mediated lysis in the presence of alemtuzumab. Blood. 2009; 114: 3052-3055.
29. Buggins AG, Mufti GJ, Salisbury J, et al. Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab. Blood. 2002; 100: 1715-1720.
30. Ratzinger G, Reagan JL, Heller G, Busam KJ, Young JW,. Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation. Blood. 2003; 101: 1422-1429.
31. Rodig SJ, Abramson JS, Pinkus GS, et al. Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H). Clin Cancer Res. 2006; 12: 7174-7179.
32. Jordan MB, McClain KL, Yan X, Hicks J, Jaffe R,. Anti-CD52 antibody, alemtuzumab, binds to Langerhans cells in Langerhans cell histiocytosis. Pediatr Blood Cancer. 2005; 44: 251-254.
33. Robak T,. Monoclonal antibodies in the treatment of chronic lymphoid leukemias. Leuk Lymphoma. 2004; 45: 205-219.